• Karim A Touijer, Robert Jeffery Karnes, Niccolo Passoni, Daniel D Sjoberg, Melissa Assel, Nicola Fossati, Giorgio Gandaglia, James A Eastham, Peter T Scardino, Andrew Vickers, Cesare Cozzarini, Francesco Montorsi, and Alberto Briganti.
• Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: touijerk@mskcc.org.
• Eur. Urol. 2018 Jun 1; 73 (6): 890-896.

BackgroundOptimal management of patients with lymph node metastasis (LNM) after radical prostatectomy (RP) remains undefined.ObjectiveWe evaluated the association between three different management strategies and survival in prostate cancer with LNM after RP.Design, Setting, And ParticipantsWe analyzed data of 1338 patients with LNM after RP from three tertiary care centers. Three hundred and eighty-seven patients (28%) were observed, 676 (49%) received lifelong adjuvant androgen deprivation therapy (ADT), and 325 (23%) received adjuvant external beam radiation therapy (EBRT) and ADT. Three hundred and sixty-eight men were followed for more than 10 yr.Outcome Measurements And Statistical AnalysisPrimary outcome measure was overall survival (OS). Secondary outcomes were cancer-specific survival (CSS) and other-cause mortality. Kaplan-Meier methods were used to visualize OS for the three treatment groups. Cox proportional hazards regression was utilized to compare OS and CSS among the three groups.Results And LimitationsADT+EBRT was associated with better OS than ADT alone (hazard ratio [HR]: 0.46, 95% confidence interval [CI]: 0.32-0.66, p<0.0001) or observation (HR: 0.41, 95% CI: 0.27-0.64, p<0.0001). Higher-risk patients benefited more from ADT+EBRT than lower-risk patients. Ten-year mortality risk difference between ADT+EBRT, observation, or ADT alone ranged from 5% in low-risk patients to 40% in high-risk patients. Adjuvant ADT+EBRT was also associated with better CSS than observation or ADT alone (p<0.0001), ADT had better CSS compared to observation (HR: 0.64, 95% CI: 0.43-0.95, p=0.027). However, ADT was associated with an increased risk of other-cause mortality (HR: 3.05, 95% CI: 1.45-6.40, p=0.003) compared with observation, resulting in similar OS between ADT and observation (HR: 0.90, 95% CI: 0.65-1.25, p=0.5). While selection bias might remain, its effect would operate in the opposite direction to our findings.ConclusionsIn men with LNM after RP, ADT+EBRT improved survival over either observation or adjuvant ADT alone. This survival benefit increases with higher-risk disease.Patient SummaryLymph node metastasis following radical prostatectomy is associated with poor survival outcomes. However, we found that adjuvant androgen deprivation therapy with external beam radiation therapy improved survival in these patients.Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

31 keywords...

hide…